> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
> See specialized channels

  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter

CEVEC again successful in challenge to Crucell patent

| Print |
Monday, 14 January 2008 10:10 (UTC + 1)


Cologne, Germany, January 14, 2008 / b3c newswire / - CEVEC Pharmaceuticals GmbH, the specialist supplier for human expression technologies, today announced that an opposition to a patent owned by Crucell N.V., Leiden, Netherlands (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX), before the European Patent Office was again successful. This is the second time within a year that the Opposition Division of the European Patent Office (EPO) has restricted a patent on Crucell’s PER.C6 cell line.

In the recently granted Europatent 1161548, Crucell tries to strengthen the patent protection surrounding its PER.C6 cell line used as a human expression system. The Opposition Division of the EPO has restricted this patent. The product claim now only relates to immortalized human embryonic retinal cells comprising a gene for monoclonal antibodies or erythropoietin. It does not protect cells used for producing human or viral proteins. This means that Crucell’s attempt of indirectly achieving extended product protection for its PER.C6 cell line as comprehensive expression system has failed.

“The marketing of CEVEC’s human expression technology is completely independent of this opposition proceeding, however. At no point was successful opposition necessary for the marketing of the CAP technology,” emphasizes Dr. Christoph Volpers, Chief Operating Officer of CEVEC Pharmaceuticals.

Yet the result of the opposition case has appreciable strategic importance for the growing market for human biotechnological production systems. CEVEC had already succeeded in an earlier opposition to Crucell’s EP patent 833 934. In both the proceedings, CEVEC was represented by Munich patent attorneys Dehmel & Bettenhausen.

About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com

CEVEC is one of the very few specialist suppliers in the world for efficient human expression technologies. Among the company’s most important developments are the CAP and PIOS technologies for industrial manufacture of biopharmaceuticals (for example, proteins and antibodies). The production of human proteins in human expression systems is becoming more and more important. CEVEC proceeds on the belief that in future many biologicals used in research and medicine will be preferentially produced in human cell lines. CEVEC’s innovative CAP and PIOS technologies are particularly suitable for this purpose, since the underlying expression technologies are based on normal human cells. The qualitative and regulatory standards required for therapeutics are strictly observed from cell isolation to production of manufacturing-grade cell lines.


For further information concerning CEVEC Pharmaceuticals GmbH:


CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 62
51105 Cologne 
Telephone: 0221-46020800
E-Mail:   This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: www.cevec-pharmaceuticals.com